Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 200Breast Neoplasms 124Carcinoma, Non-Small-Cell Lung 121Glioblastoma 93Neoplasms 75Ovarian Neoplasms 72Rectal Neoplasms 61Brain Neoplasms 59Lung Neoplasms 56Colonic Neoplasms 55Neoplasm Metastasis 51Glioma 49Carcinoma, Renal Cell 46Fallopian Tube Neoplasms 38Gliosarcoma 35Pancreatic Neoplasms 31Carcinoma, Hepatocellular 28Melanoma 26Adenocarcinoma of Lung 24Stomach Neoplasms 21Astrocytoma 21Uterine Cervical Neoplasms 16Recurrence 16Prostatic Neoplasms 16Liver Neoplasms 16Adenocarcinoma, Bronchiolo-Alveolar 16Adenocarcinoma 16Esophageal Neoplasms 15Carcinoma, Ovarian Epithelial 14Kidney Neoplasms 13

Interventions

rucaparib 1fludarabine 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Paclitaxel 1Nivolumab 1Melphalan 1Erlotinib Hydrochloride 1Carboplatin 1Busulfan 1Bevacizumab 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma, Clear Cell × Bevacizumab × Clear all
NCT00455975 2014-12-22

High-dose Bevacizumab in Advanced Renal Carcinoma Patients

SCRI Development Innovations, LLC

Phase 2 Completed
119 enrolled 8 charts
Genitourinary

Kidney Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡